Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement
Ella Day | May 14, 2025 | News story | Research and Development | Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement
Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate the development of Secarna’s oligonucleotide therapeutics.
Under the agreement, Secarna will leverage its OligoCreator platform in exchange for a technology access fee, research funding and warrants to purchase shares in Cure.Bio upon the achievement of predefined milestones.
The OligoCreator platform identifies and characterises oligonucleotide therapeutics with speed and efficacy using artificial intelligence, delivery technologies, and its safety and efficacy testing systems. These targeted oligonucleotide therapies have the potential to transform treatments for a range of disorders that are difficult to treat. The collaboration validates the platform as a potentially pivotal tool.
Describing itself as “both a drug discovery copilot and investor,” Curebio directly invests in new medicines. Its Seed Fund focuses on advancing therapies through preclinical milestones, such as selecting a development candidate, and its Breakout Fund focuses on advancing medicines through clinical trials.
“We are excited to collaborate with Curie.Bio and their portfolio company who share our vision for transforming scientific innovation into life-changing therapies,” said CEO of Secarna, Konstantin Petropoulos.
He added: “Together aim to unlock new possibilities for patients suffering from diseases that are difficult to treat with conventional approaches.”
Ella Day
14/5/25
Related Content
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant
Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling …
Secarna Pharmaceuticals to announce positive new data at cancer research conference
Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American …
